Navigation Links
Pharmacyclics to Present at the RBC Capital Markets Healthcare Investor Conference
Date:2/26/2010

SUNNYVALE, Calif., Feb. 26 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune mediated diseases and cancer, announced that the Company will be participating at the RBC Capital Markets Healthcare Investor Conference in New York at the Palace Hotel on Tuesday, March 2nd. Dr. Joseph Buggy, Vice President of Research, will be on a panel titled, "New Targets in Cancer Therapy" starting at 8:00 A.M. Eastern Time and moderated by RBC analyst Jason Kantor.  

There will be a live webcast of the panel, which will be accessible through a link posted on the investor relations / events & webcasts section of the PCYC website, please go to http://ir.pharmacyclics.com/events.cfm

About Pharmacyclics

Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of immune mediated disease and cancer. The purpose of the company is to create a profitable business by generating income from products it develops, licenses and commercializes, either with one or several potential partners or alone as may best forward the economic interest of its stakeholders. The Company endeavors to create novel, patentable, differentiated products that have the potential to significantly improve the standard of care in the markets it serves. Presently, Pharmacyclics has four product candidates in clinical development and two product candidates in pre-clinical development. It is Pharmacyclics' business strategy to establish collaborations with large pharmaceutical and biotechnology companies for the purpose of generating present and future income in exchange for adding to their product pipelines. Pharmacyclics strives to generate collaborations that allow it to retain valuable territorial rights and simultaneously fast forward the clinical development and commercialization of its products. The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.

SOURCE Pharmacyclics, Inc.

Back to top

RELATED LINKS
http://www.pharmacyclics.com

'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results
2. Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hematology Meeting Dec. 6 & 7
3. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
4. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
5. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
6. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
7. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
8. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
9. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
10. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
11. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 2017  The Global Health Innovative Technology Fund ... to battle infectious diseases around the globe, today ... could help deliver a range of new innovative ... This latest round of targeted support ... testing a pediatric formulation of a drug considered ...
(Date:3/29/2017)... -- The leader in accelerated orthodontics, OrthoAccel ® Technologies, ... Manal Ibrahim , Kenji Ojima , ... featured microlecture presenters at the AcceleDent ® booth ... Annual Session, April 21-25, 2017. Orthodontists and their staff ... 11:20 a.m. On the opening morning of AAO exhibitions, ...
(Date:3/29/2017)... 2017 Transparency Market Research ... an exhaustive study of the U.S. substance abuse treatment ... are functional in this market at present, making ... companies, such as GlaxoSmithKline Plc., Pfizer Inc., Alkermes ... various marketing strategies to increase their visibility, the ...
Breaking Medicine Technology:
(Date:3/29/2017)... , ... March 29, 2017 , ... In the United ... 300,000 people each year develop other types of metastatic brain tumors(3). Though most meningiomas ... brain(3). As efforts focus on finding more effective treatment options, the San Diego ...
(Date:3/29/2017)... ... 2017 , ... Full Contact K9, an Atlanta-based dog services provider, has recently ... assists dog owners in creating legally-enforceable pet trusts for their canine companions. , ... to protect their new companion. Says Evan Dunbar, CEO of Full Contact K9, “When ...
(Date:3/29/2017)... ... March 30, 2017 , ... CHARM CITY RUN WELCOMES MERCY MEDICAL ... that Mercy Medical Center will serve as the official title sponsor of the Baltimore ... June 25, 2017, thousands of women will walk or run the course around the ...
(Date:3/29/2017)... ... March 30, 2017 , ... Sublime Naturals and its founder, ... or "Wonder Spice", it has been used for thousands of years. , "The West ... Heshelow, author of " Turmeric: How to Use it For Your Wellness. Overcome Inflammation, ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... ... hosting several educational opportunities for attending prescribers at the upcoming World Congress, in ... said, “A4M has always been recognized as the visionary leader in the training ...
Breaking Medicine News(10 mins):